Galmed Pharma（GLMD）宣布Aramchol的最新摘要将在AASLD上发布 文章

StephenW

Galmed Pharma (GLMD) Announces Late-Breaking Abstract on Aramchol to be Presented at AASLD
Article

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH"), announced today that a late-breaking abstract on the one-year results of a Phase 2b study of Aramchol in patients with NASH will be presented by the Company at the American Association for the Study of Liver Diseases – The Liver Meeting®, taking place November 9–13, 2018 in San Francisco, California. The oral session will be presented by Prof. Vlad Ratziu, France, principal investigator of the ARREST trial. More data on Aramchol anti fibrotic effect will be presented in a poster presentation.

ARREST is a multicenter, Phase 2b, randomized, double blind, placebo-controlled study designed to evaluate the efficacy and safety of two Aramchol doses (400 and 600 mg tablets) in patients with NASH confirmed by liver biopsy who were overweight or obese and who were pre- diabetic or type II diabetic. Top line results from the study were released by Galmed on June 12, 2018.

Oral Abstract Presentation Details:

Date: Tuesday, November 12, 2018Time: 8:00am Pacific TimeLocation: Hall D - General Session, Moscone Center, North and South BuildingsPublication #: LB-5Session Title: Late-Breaking Abstract Oral Session IIPresentation Type: Oral, Late-Breaker SessionTitle: One-Year Results of the Global Phase 2b Randomized Placebo-Controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturase Inhibitor, in Patients with NASH

Poster Abstract Presentation Details:

Date: Monday, November 13, 2018Time: 8:00am – 5:30pm Pacific TimePublication #: 2060Poster Session Title: Steatohepatitis: ExperimentalPresentation Type: PosterTitle: Aramchol downregulates SCD1 and induces PPAR g in hepatic stellate cells to attenuate cellular activation and fibrogenesis.

StephenW

Galmed Pharma（GLMD）宣布Aramchol的最新摘要将在AASLD上发布
文章

Galmed Pharmaceuticals Ltd.（纳斯达克股票代码：GLMD）（“Galmed”或“公司”），一家临床阶段的生物制药公司，专注于肝脏靶向SCD1调节剂Aramchol™的开发，Aramchol™是一种每日一次的口服疗法，用于治疗非酒精性脂肪性肝炎（“NASH”）今天宣布，该公司将在美国肝病研究协会提交关于NASH患者Aramchol 2b期研究的一年结果的最新摘要 - 肝脏会议®于2018年11月9日至13日在加利福尼亚州旧金山举行。口述会议将由法国Vlad Ratziu教授介绍，他是ARREST试验的首席研究员。有关Aramchol抗纤维化作用的更多数据将在海报展示中呈现。

ARREST是一项多中心，2b期，随机，双盲，安慰剂对照研究，旨在评估两种Aramchol剂量（400和600 mg片剂）对肝活检证实超重或肥胖的NASH患者的疗效和安全性是糖尿病前期或II型糖尿病患者。该研究的最佳结果由Galmed于2018年6月12日发布。

口头抽象演讲细节：

日期：2018年11月12日，星期二时间：太平洋时间上午8:00地点：D厅 - 大会，Moscone中心，南北建筑物出版物＃：LB-5Session标题：最新的抽象口头会议IIPresentation类型：口头，晚期会议标题：NASH患者Aramchol（一种硬脂酰辅酶A去饱和酶抑制剂）的全球2b期随机安慰剂对照ARREST试验的一年结果

海报摘要介绍详情：

日期：2018年11月13日，星期一时间：太平洋时间上午8:00 - 下午5:30出版＃：2060Poster会议题目：脂肪性肝炎：实验表现类型：PosterTitle：Aramchol下调SCD1并诱导肝星状细胞中的PPAR g以减弱细胞活化和纤维发生。